James Ryan - BioNTech Sr Counsel
| 22UA Stock | EUR 118.90 1.90 1.62% |
Insider
James Ryan is Sr Counsel of BioNTech SE
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
James Ryan Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Ryan against BioNTech stock is an integral part of due diligence when investing in BioNTech. James Ryan insider activity provides valuable insight into whether BioNTech is net buyers or sellers over its current business cycle. Note, BioNTech insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioNTech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Ryan over six months ago Disposition of 130000 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Payment of 15970 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Payment of 10936 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Acquisition by James Ryan of 1883 shares of Ballys Corp subject to Rule 16b-3 |
BioNTech Management Efficiency
The company has return on total asset (ROA) of 0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ray Jordan | Moderna | N/A | |
| James Mock | Moderna | 46 | |
| Robert Borin | Nel ASA | N/A | |
| Hakon Volldal | Nel ASA | 47 | |
| Qian Li | BYD Company Limited | 50 | |
| Jorn Rosenlund | Nel ASA | N/A | |
| JingSheng Wu | BYD Company Limited | 60 | |
| Yubo Lian | BYD Company Limited | 59 | |
| Paul Sagan | Moderna | 59 | |
| HongBin Luo | BYD Company Limited | 57 | |
| Patrik Brouzell | Powercell Sweden | 45 | |
| Pierre BSc | CureVac NV | 48 | |
| Shannon Klinger | Moderna | 52 | |
| Robert Langer | Moderna | 73 | |
| John Reynders | Moderna | N/A | |
| Marco LLM | CureVac NV | N/A | |
| Jerh Collins | Moderna | N/A | |
| Melissa Moore | Moderna | N/A | |
| Magnus Jonsson | Powercell Sweden | 63 | |
| Dirk Boever | Powercell Sweden | 49 | |
| LLM LLM | CureVac NV | 52 | |
Management Performance
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein, CFO Board | ||
| Sylke Maas, VP Strategy | ||
| James Ryan, Sr Counsel | ||
| Michael Boehler, MD Communications | ||
| Ryan Richardson, MD Officer | ||
| Sierk Poetting, COO MD | ||
| Pr MD, CoFounder Board | ||
| Ozlem MD, Chief CoFounder | ||
| Sean Marett, Chief Officer |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Shares Owned By Insiders | 64.00 % | |||
| Shares Owned By Institutions | 18.41 % | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.